- Report
- April 2025
- 92 Pages
Global
From €5369EUR$5,600USD£4,486GBP
- Report
- March 2025
- 200 Pages
Global
From €4304EUR$4,490USD£3,597GBP
- Report
- March 2025
- 250 Pages
Global
From €4304EUR$4,490USD£3,597GBP
- Report
- December 2024
- 175 Pages
Global
From €4793EUR$5,000USD£4,005GBP
- Report
- May 2024
- 139 Pages
Global
From €6230EUR$6,499USD£5,206GBP
- Report
- February 2023
- 250 Pages
Global
From €4793EUR$5,000USD£4,005GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1198EUR$1,250USD£1,001GBP
- Report
- August 2022
- 120 Pages
Global
From €4554EUR$4,750USD£3,805GBP
- Book
- September 2023
- 288 Pages
- Book
- July 2023
- 1568 Pages
- Book
- July 2015
- 328 Pages
Ivermectin is an anti-parasitic drug used to treat a variety of infectious diseases, including river blindness, scabies, and strongyloidiasis. It is a broad-spectrum antiparasitic drug, meaning it is effective against a wide range of parasites. Ivermectin is also used to treat head lice and is available in both topical and oral forms. It is generally well-tolerated and has few side effects.
Ivermectin is a widely used drug in the treatment of infectious diseases, and its market is growing. It is used in both human and veterinary medicine, and is increasingly being used in the treatment of neglected tropical diseases. Ivermectin is also being studied for its potential use in the treatment of other diseases, such as cancer and HIV.
Some companies in the Ivermectin market include Merck & Co., Inc., Pfizer, Inc., Sanofi, Bayer AG, and Novartis AG. Show Less Read more